Cryptococcal meningitis in a patient receiving Rituximab and Bendamustine for marginal zone lymphoma

被引：0
|
作者：
Kyriazopoulou, E. [1 ]
Pickert, A. [2 ]
Kuntz, R. [3 ]
Martens, U. [1 ]
Lindauer, M. [1 ]
机构：
[1] SLK Klinikum Gesundbrunnen, Med Klin Hamatol Onkol 3, Heilbronn, Germany
[2] SLK Klinikum Gesundbrunnen, Inst Lab Med & Blutbank, Heilbronn, Germany
[3] SLK Klinikum Gesundbrunnen, Inst Radiol & Minimalinvas Med, Heilbronn, Germany
来源：
ONKOLOGIE | 2013年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：11 / 11
页数：1
相关论文
共 50 条
  • [31] Cryptococcal meningitis in a patient with non-Hodgkin's lymphoma
    Kilani, B.
    Benaiss, H. Tiouiri
    Ammari, L.
    Chaker, E.
    Ben Chaabane, T.
    JOURNAL DE MYCOLOGIE MEDICALE, 2007, 17 (03): : 191 - 193
  • [32] Case Report: Cryptococcal eosinophilic meningitis in a patient with Hodgkin lymphoma
    Zhang, Fang
    Li, Yuchen
    Shen, Huijun
    Tao, Jie
    Wang, Jie
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [33] Successful rechallenge of rituximab following severe rituximab-induced acute thrombocytopenia in a patient with splenic marginal zone lymphoma
    Robinson, Adam C.
    Nachar, Victoria R.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (05) : 1248 - 1253
  • [34] Rituximab monotherapy in splenic marginal zone lymphoma instead of splenectomy
    Bennett, M.
    Yegena, S.
    Chubar, E.
    Schechter, G. P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 : 45 - 45
  • [35] Rituximab monotherapy is highly effective in splenic marginal zone lymphoma
    Kalpadakis, C.
    Pangalis, G. A.
    Dimopoulou, M. N.
    Vassilakopoulos, T. P.
    Kyrtsonis, M-C
    Korkolopoulou, P.
    Kontopidou, F. N.
    Siakantaris, M. P.
    Dimitriadou, E. M.
    Kokoris, S. I.
    Tsaftaridis, P.
    Plata, E.
    Angelopoulou, M. K.
    HEMATOLOGICAL ONCOLOGY, 2007, 25 (03) : 127 - 131
  • [36] Role of rituximab in the treatment of splenic marginal zone lymphoma.
    Al Shehadat, S
    Bast, MA
    Sehi, G
    Bociek, GR
    Kessinger, A
    Armitage, JO
    BLOOD, 2005, 106 (11) : 253B - 254B
  • [37] Rituximab monotherapy is highly effective in splenic marginal zone lymphoma
    Bennett, Michael
    Yegena, Shaiy
    Dave, Harish P.
    Schechter, Geraldine P.
    HEMATOLOGICAL ONCOLOGY, 2008, 26 (02) : 114 - 114
  • [38] SPLENECTOMY VERSUS RITUXIMAB IN THE TREATMENT OF SPLENIC MARGINAL ZONE LYMPHOMA
    Kalpadakis, C.
    Pangalis, G. A.
    Vassilakopoulos, T. P.
    Sachanas, S.
    Kyrtsonis, M. C.
    Dimopoulou, M.
    Korkolopoulou, P.
    Kontopidou, F. N.
    Yiakoumis, X.
    Siakantaris, M. P.
    Dimitriadou, E. M.
    Panayiotidis, P.
    Papadaki, H.
    Angelopoulou, M. K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 168 - 169
  • [39] Treatment of Splenic Marginal Zone Lymphoma: Splenectomy Versus Rituximab
    Bennett, Michael
    Schechter, Geraldine P.
    SEMINARS IN HEMATOLOGY, 2010, 47 (02) : 143 - 147
  • [40] Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma)
    Barbara Kiesewetter
    Marius E. Mayerhoefer
    Julius Lukas
    Christoph C. Zielinski
    Leonhard Müllauer
    Markus Raderer
    Annals of Hematology, 2014, 93 : 249 - 253
12345